New US tariff measures and acute geopolitical tensions are reshaping the global pharmaceutical landscape, prompting companies to reassess supply chains and production strategies, GlobalData has reported.
US tariffs
The US administration’s decision to impose tariffs on imported pharmaceuticals and their ingredients has upended decades of medicines trade orthodoxy, the intelligence platform said.
New policy introduced a complex system of incentives tied to domestic manufacturing and pricing agreements.
Simultaneously, a strong focus on onshoring underscores a broader push to strengthen US production capacity, GlobalData reported.
Dominic Tyer, Senior Editor, GlobalData, commented: “The tariff framework fundamentally changes the operating environment for global pharma.
“While pricing agreements remain relevant, US priorities have been more closely calibrated around onshoring manufacturing, with companies now under even greater pressure to align their production footprints with policy expectations.”
GlobalData predicts that the shift will continue to drive increased investment in US-based manufacturing, building on the tens of billions of dollars that major pharmaceutical companies have already committed to expand their domestic capacities.
Conflict in the Middle East
GlobalData’s April 2026 Bio/Pharmaceutical Outsourcing Report, a monthly analysis of trends affecting pharmaceutical Contract Manufacturing Organisations, notes that the ongoing conflict in the Middle East is adding further strains for pharma manufacturing.
Rising energy prices, disrupted logistics routes and higher freight costs are increasing production expenses and supply chain uncertainty, the report found.
Edita Hamzic, Healthcare Analyst, GlobalData, said: “The current geopolitical environment is intensifying existing vulnerabilities.
“Supply chains remain highly concentrated and cost sensitive.
“Even moderate disruptions can have downstream effects on medicine availability and pricing.”
The impact is reportedly widespread: the US faces heightened risk due to its dependence on imported generics and similar vulnerabilities exist in the EU and UK.
In Asia-Pacific, energy dependence and currency pressures are increasing production costs.
Hamzic concluded: “The addition of geopolitical tension to the US push to onshore pharma manufacturing will increase pressure on companies to rewire supply chains and production strategies, while also forcing them to evaluate the real-world effects of extraordinary trade policy changes.”
Featured image: Aerial View on Adobe Stock
